文献速递眼底病与葡萄膜炎

抗VEGF治疗新生血管性AMD期间视网膜内液的发生与危险因素

Development of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration During Anti-Vascular Endothelial Growth Factor Treatment.
PubMed 文献 · Am J Ophthalmol · 2021-07-30

本研究为回顾性队列研究,纳入425例完成24个月随访的初治新生血管性AMD患者,均接受3次每月负荷剂量抗VEGF注射后按需治疗。结果显示40.2%(171/425眼)在维持期出现视网膜内液(IRF),且IRF发生对视力结局有额外负面影响;基线较大的脉络膜新生血管面积、基线存在IRF、纤维血管性色素上皮脱离及MNV亚型与IRF发生风险升高相关。

要点

  • 抗VEGF维持期40.2%患眼出现IRF,且无论基线有无IRF均损害视力结局。
  • 基线存在IRF者后续IRF风险最高(OR 5.469)。
  • 基线脉络膜新生血管面积较大、纤维血管性PED及1型/2型MNV亦增加IRF风险。

核心结论

  • 抗VEGF治疗新生血管性AMD期间发生IRF对视力结局有额外负面影响,与基线是否存在IRF无关。
  • 基线脉络膜新生血管面积、基线IRF、纤维血管性色素上皮脱离及MNV亚型可能影响治疗期间IRF的发生。

研究设计与样本

  • 回顾性队列研究,纳入425例完成24个月随访的初治新生血管性AMD患者。
  • 所有患者接受初始3次每月负荷剂量抗VEGF注射,随后按需注射。
  • 采用多变量模型评估基线特征对IRF发生的潜在危险因素。

主要发现

  • 维持期40.2%(171/425眼)出现IRF。
  • 多变量分析显示较大脉络膜新生血管面积(OR 1.360;P < .001)与IRF风险升高相关。
  • 基线存在IRF(OR 5.469;P < .001)与IRF风险升高相关。
  • 纤维血管性色素上皮脱离(OR 2.043;P = .022)与IRF风险升高相关。
  • 1型(OR 2.005;P = .037)和2型MNV(OR 2.643;P = .009)较动脉瘤型1型MNV/息肉状脉络膜血管病变的IRF风险更高。

临床怎么用

  • 对基线存在IRF、较大脉络膜新生血管面积、纤维血管性PED或1型/2型MNV的患者,抗VEGF治疗中应警惕IRF发生。
  • 随访中需关注IRF出现,因其与视力结局不良相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify the risk factors of intraretinal fluid (IRF) development during anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). DESIGN: Retrospective cohort study. METHODS: A total of 425 treatment-naïve patients with neovascular AMD who completed 24 months of follow-up were enrolled. All patients were treated with an initial series of 3 monthly loading doses of anti-VEGF injections, followed by further injections as required. Baseline characteristics were evaluated using multivariate modeling to determine the potential risk factors for IRF development. RESULTS: IRF occurred in 40.2% (171/425 eyes) of all participants during the maintenance phase after the loading injections. The development of IRF during follow-up negatively affected visual outcomes regardless of the presence of IRF at baseline. Multivariate analysis showed that larger areas of choroidal neovascularization (odds ratio [OR] 1.360; P < .001), the presence of IRF at baseline (OR 5.469; P < .001), and the presence of fibrovascular pigment epithelial detachment (OR 2.043; P = .022) were associated with an increased risk of IRF during follow-up. Type 1 (OR 2.005; P = .037) and type 2 macular neovascularization (MNV) (OR 2.643; P = .009) were also associated with a higher risk of IRF than aneurysmal type 1 MNV/polypoidal choroidal vasculopathy. CONCLUSIONS: The development of IRF during anti-VEGF treatment for neovascular AMD has additional negative effects on visual outcomes regardless of the presence of IRF at baseline. Baseline risk factors, including choroidal neovascularization size, presence of IRF at baseline, presence of fibrovascular pigment epithelial detachment, and MNV subtype may influence the development of IRF during anti-VEGF treatment.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cho HJ, Yoon W, Yoon J, et al. Development of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration During Anti-Vascular Endothelial Growth Factor Treatment. Am J Ophthalmol. 2021. PMID: 34339661. doi:10.1016/j.ajo.2021.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。